ANA Therapeutics, a Silicon Valley-based biotech startup, and Quotient Sciences, a leading provider of drug development today announced a partnership to support the manufacturing of ANA Therapeutics’ drug candidate. The drug candidate, ANA001 (niclosamide capsules), is being developed as a potential treatment for COVID-19. Quotient Sciences is a portfolio company of Permira.
The selection of the Permira Portfolio company was an important one, which Andrew Bartynski, COO, ANA Therapeutics, cited: “We have selected Quotient Sciences as our development and manufacturing partner and our plan is simple."
When speaking about the COVID-19 drug in development, he said: Niclosamide has the potential to be an effective antiviral agent to combat COVID-19, and our top goal is ...
